{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,27]],"date-time":"2026-10-27T13:23:00Z","timestamp":1793107380445,"version":"4.5.0"},"reference-count":46,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,11,1]],"date-time":"2024-11-01T00:00:00Z","timestamp":1730419200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,11,1]],"date-time":"2024-11-01T00:00:00Z","timestamp":1730419200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,11,1]],"date-time":"2024-11-01T00:00:00Z","timestamp":1730419200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2024,11,1]],"date-time":"2024-11-01T00:00:00Z","timestamp":1730419200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2024,11,1]],"date-time":"2024-11-01T00:00:00Z","timestamp":1730419200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2024,11,1]],"date-time":"2024-11-01T00:00:00Z","timestamp":1730419200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2024,11,1]],"date-time":"2024-11-01T00:00:00Z","timestamp":1730419200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.com.au","clinicalkey.es","jpeds.com","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["The Journal of Pediatrics"],"published-print":{"date-parts":[[2024,11]]},"DOI":"10.1016\/j.jpeds.2024.114176","type":"journal-article","created":{"date-parts":[[2024,6,28]],"date-time":"2024-06-28T06:56:04Z","timestamp":1719557764000},"page":"114176","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":27,"special_numbering":"C","title":["Reported Adverse Events in a Multicenter Cohort of Patients Ages 6-18\u00a0Years with Cystic Fibrosis and at Least One F508del Allele Receiving Elexacaftor\/Tezacaftor\/Ivacaftor"],"prefix":"10.1016","volume":"274","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1106-4424","authenticated-orcid":false,"given":"Vito","family":"Terlizzi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cristina","family":"Fevola","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Santiago","family":"Presti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alice","family":"Castaldo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Valeria","family":"Dacc\u00f2","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura","family":"Claut","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Angela","family":"Sepe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fabio","family":"Majo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rosaria","family":"Casciaro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Irene","family":"Esposito","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pamela","family":"Vitullo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marta","family":"Salvi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patrizia","family":"Troiani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesca","family":"Ficili","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giuseppe Fabio","family":"Parisi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefano","family":"Pantano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefano","family":"Costa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giuseppina","family":"Leonetti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicola","family":"Palladino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giovanni","family":"Taccetti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paolo","family":"Bonomi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Donatello","family":"Salvatore","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jpeds.2024.114176_bib1","doi-asserted-by":"crossref","first-page":"1859","DOI":"10.1001\/jama.2023.8120","article-title":"Cystic fibrosis: a review","volume":"329","author":"Ong","year":"2023","journal-title":"JAMA"},{"key":"10.1016\/j.jpeds.2024.114176_bib2","doi-asserted-by":"crossref","first-page":"1693","DOI":"10.1056\/NEJMra2216474","article-title":"Cystic fibrosis","volume":"389","author":"Grasemann","year":"2023","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jpeds.2024.114176_bib3","doi-asserted-by":"crossref","first-page":"1185","DOI":"10.1016\/S0140-6736(23)01608-2","article-title":"The future of cystic fibrosis treatment: from disease mechanisms to novel therapeutic approaches","volume":"402","author":"Graeber","year":"2023","journal-title":"Lancet"},{"key":"10.1016\/j.jpeds.2024.114176_bib4","doi-asserted-by":"crossref","first-page":"963","DOI":"10.1016\/j.jcf.2023.09.008","article-title":"Standards for the care of people with cystic fibrosis (CF): a timely and accurate diagnosis","volume":"22","author":"Castellani","year":"2023","journal-title":"J Cyst Fibros"},{"key":"10.1016\/j.jpeds.2024.114176_bib5","doi-asserted-by":"crossref","first-page":"1662","DOI":"10.3389\/fphar.2019.01662","article-title":"CFTR modulators: the changing face of cystic fibrosis in the era of precision medicine","volume":"10","author":"Lopes-Pacheco","year":"2019","journal-title":"Front Pharmacol"},{"key":"10.1016\/j.jpeds.2024.114176_bib6","article-title":"Corrector therapies (with or without potentiators) for people with cystic fibrosis with class II CFTR gene variants (most commonly F508del)","volume":"12","author":"Southern","year":"2020","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.jpeds.2024.114176_bib7","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/j.jcf.2022.10.002","article-title":"Standards of care for CFTR variant-specific therapy (including modulators) for people with cystic fibrosis","volume":"22","author":"Southern","year":"2023","journal-title":"J Cyst Fibros"},{"key":"10.1016\/j.jpeds.2024.114176_bib8","doi-asserted-by":"crossref","first-page":"1809","DOI":"10.1056\/NEJMoa1908639","article-title":"Elexacaftor-tezacaftor-ivacaftor for cystic fibrosis with a single Phe508del allele","volume":"381","author":"Middleton","year":"2019","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jpeds.2024.114176_bib9","doi-asserted-by":"crossref","first-page":"1769","DOI":"10.3390\/cells11111769","article-title":"CFTR modulators in people with cystic fibrosis: real-world evidence in France","volume":"11","author":"Regard","year":"2022","journal-title":"Cells"},{"key":"10.1016\/j.jpeds.2024.114176_bib10","doi-asserted-by":"crossref","DOI":"10.1183\/13993003.00110-2023","article-title":"Theratyping cystic fibrosis patients to guide elexacaftor\/tezacaftor\/ivacaftor out-of-label prescription","volume":"62","author":"Dreano","year":"2023","journal-title":"Eur Respir J"},{"key":"10.1016\/j.jpeds.2024.114176_bib11","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1016\/j.jcf.2022.10.011","article-title":"Treatment effects of Elexacaftor\/Tezacaftor\/Ivacaftor in people with CF carrying non-F508del mutations","volume":"22","author":"Livnat","year":"2023","journal-title":"J Cyst Fibros"},{"key":"10.1016\/j.jpeds.2024.114176_bib12","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1080\/17476348.2023.2179989","article-title":"Managing cystic fibrosis in children aged 6-11yrs: a critical review of elexacaftor\/tezacaftor\/ivacaftor combination therapy","volume":"17","author":"Jordan","year":"2023","journal-title":"Expert Rev Respir Med"},{"key":"10.1016\/j.jpeds.2024.114176_bib13","doi-asserted-by":"crossref","first-page":"1612","DOI":"10.1056\/NEJMoa1807120","article-title":"VX-445-tezacaftor-ivacaftor in patients with cystic fibrosis and one or two Phe508del alleles","volume":"379","author":"Keating","year":"2018","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jpeds.2024.114176_bib14","doi-asserted-by":"crossref","first-page":"730","DOI":"10.1016\/j.jcf.2023.03.002","article-title":"Real-world safety and effectiveness of elexacaftor\/tezacaftor\/ivacaftor in people with cystic fibrosis: interim results of a long-term registry-based study","volume":"22","author":"Bower","year":"2023","journal-title":"J Cyst Fibros"},{"key":"10.1016\/j.jpeds.2024.114176_bib15","doi-asserted-by":"crossref","first-page":"1021","DOI":"10.3390\/jcm11041021","article-title":"Elexacaftor\/Tezacaftor\/Ivacaftor in patients with cystic fibrosis homozygous for the F508del mutation and advanced lung disease: a 48-week observational study","volume":"11","author":"Carnovale","year":"2022","journal-title":"J Clin Med"},{"key":"10.1016\/j.jpeds.2024.114176_bib16","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1164\/rccm.202301-0021OC","article-title":"Long-term safety and efficacy of Elexacaftor\/Tezacaftor\/Ivacaftor in children aged \u2a7e6 years with cystic fibrosis and at least one F508del allele: a phase 3, open-label clinical trial","volume":"208","author":"Wainwright","year":"2023","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.jpeds.2024.114176_bib17","doi-asserted-by":"crossref","first-page":"677","DOI":"10.1016\/j.ccm.2022.06.009","article-title":"Update on clinical outcomes of highly effective modulator therapy","volume":"43","author":"Gifford","year":"2022","journal-title":"Clin Chest Med"},{"key":"10.1016\/j.jpeds.2024.114176_bib18","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1164\/rccm.202301-0084OC","article-title":"Phase 3 open-label clinical trial of Elexacaftor\/Tezacaftor\/Ivacaftor in children aged 2-5 years with cystic fibrosis and at least one F508del allele","volume":"208","author":"Goralski","year":"2023","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.jpeds.2024.114176_bib19","doi-asserted-by":"crossref","first-page":"662","DOI":"10.1016\/S2213-2600(16)00023-0","article-title":"Progress in therapies for cystic fibrosis","volume":"4","author":"De Boeck","year":"2016","journal-title":"Lancet Respir Med"},{"key":"10.1016\/j.jpeds.2024.114176_bib20","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2023.1163391","article-title":"Real-world disparities and ethical considerations with access to CFTR modulator drugs: mind the gap!","volume":"14","author":"Zampoli","year":"2023","journal-title":"Front Pharmacol"},{"key":"10.1016\/j.jpeds.2024.114176_bib21","doi-asserted-by":"crossref","DOI":"10.1177\/17534666221144211","article-title":"Impact of elexacaftor\/tezacaftor\/ivacaftor on depression and anxiety in cystic fibrosis","volume":"16","author":"Zhang","year":"2022","journal-title":"Ther Adv Respir Dis"},{"key":"10.1016\/j.jpeds.2024.114176_bib22","doi-asserted-by":"crossref","first-page":"885","DOI":"10.1016\/j.jcf.2022.04.010","article-title":"Onset of systemic arterial hypertension after initiation of Elexacaftor\/Tezacaftor\/Ivacaftor in adults with cystic fibrosis: a case series","volume":"21","author":"Gramegna","year":"2022","journal-title":"J Cyst Fibros"},{"key":"10.1016\/j.jpeds.2024.114176_bib23","doi-asserted-by":"crossref","first-page":"1061","DOI":"10.1016\/j.jcf.2022.05.001","article-title":"Dose adjustments of Elexacaftor\/Tezacaftor\/Ivacaftor in response to mental health side effects in adults with cystic fibrosis","volume":"21","author":"Spoletini","year":"2022","journal-title":"J Cyst Fibros"},{"key":"10.1016\/j.jpeds.2024.114176_bib24","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1016\/j.jcf.2023.01.015","article-title":"Suicide attempts in adolescents with cystic fibrosis on Elexacaftor\/Tezacaftor\/Ivacaftor therapy","volume":"22","author":"Arslan","year":"2023","journal-title":"J Cyst Fibros"},{"key":"10.1016\/j.jpeds.2024.114176_bib25","doi-asserted-by":"crossref","first-page":"1077","DOI":"10.1016\/j.jcf.2022.06.011","article-title":"A case of Elexacaftor-Tezacaftor-Ivacaftor induced rash resolving without interruption of treatment","volume":"21","author":"Bhaskaran","year":"2022","journal-title":"J Cyst Fibros"},{"key":"10.1016\/j.jpeds.2024.114176_bib26","doi-asserted-by":"crossref","first-page":"3626","DOI":"10.1002\/ppul.26673","article-title":"Prevalence of adverse events in cystic fibrosis patients treated with elexacaftor\/tezacaftor\/ivacaftor: experience of the regional referral center in Tuscany","volume":"58","author":"Manciulli","year":"2023","journal-title":"Italy, Pediatr Pulmonol"},{"key":"10.1016\/j.jpeds.2024.114176_bib27","first-page":"463","article-title":"Rechallenge of Elexacaftor\/Tezacaftor\/Ivacaftor after skin rash in two pediatric patients","volume":"27","author":"Diseroad","year":"2022","journal-title":"J Pediatr Pharmacol Ther"},{"key":"10.1016\/j.jpeds.2024.114176_bib28","doi-asserted-by":"crossref","first-page":"1130","DOI":"10.1016\/j.jcf.2023.06.013","article-title":"Hyperbilirubinemia and Gilbert\u2019s syndrome in cystic fibrosis patients treated with Elexacaftor\/Tezacaftor\/Ivacaftor","volume":"22","author":"Terlizzi","year":"2023","journal-title":"J Cyst Fibros"},{"key":"10.1016\/j.jpeds.2024.114176_bib29","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1016\/j.jcf.2021.10.002","article-title":"Mental status changes during Elexacaftor\/Tezacaftor\/Ivacaftor therapy","volume":"21","author":"Heo","year":"2022","journal-title":"J Cyst Fibros"},{"key":"10.1016\/j.jpeds.2024.114176_bib30","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1164\/rccm.202303-0380LE","article-title":"Raised intracranial pressure in three children with cystic fibrosis receiving elexacaftor-tezacaftor-ivacaftor modulator therapy","volume":"208","author":"Southern","year":"2023","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.jpeds.2024.114176_bib31","doi-asserted-by":"crossref","first-page":"106646","DOI":"10.1016\/j.rmed.2021.106646","article-title":"Effectiveness and safety of Elexacaftor\/Tezacaftor\/Ivacaftor in patients with cystic fibrosis and advanced lung disease with the Phe508del\/minimal function genotype","volume":"189","author":"Carnovale","year":"2021","journal-title":"Respir Med"},{"key":"10.1016\/j.jpeds.2024.114176_bib35","doi-asserted-by":"crossref","first-page":"2191","DOI":"10.1001\/jama.2013.281053","article-title":"World Medical Association Declaration of Helsinki: ethical principles for medical research involving human subjects","volume":"310","year":"2013","journal-title":"JAMA"},{"key":"10.1016\/j.jpeds.2024.114176_bib37","doi-asserted-by":"crossref","first-page":"1220","DOI":"10.1097\/HEP.0000000000000646","article-title":"Cystic fibrosis screening, evaluation, and management of hepatobiliary disease consensus recommendations","volume":"79","author":"Sellers","year":"2024","journal-title":"Hepatology"},{"key":"10.1016\/j.jpeds.2024.114176_bib39","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1016\/j.jcf.2024.01.005","article-title":"Standards for the care of people with cystic fibrosis (CF); recognising and addressing CF health issues","volume":"23","author":"Burgel","year":"2024","journal-title":"J Cyst Fibros"},{"key":"10.1016\/j.jpeds.2024.114176_bib40","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1097\/MCP.0000000000001014","article-title":"Neuropsychiatric adverse effects from CFTR modulators deserve a serious research effort","volume":"29","author":"VanElzakker","year":"2023","journal-title":"Curr Opin Pulm Med"},{"key":"10.1016\/j.jpeds.2024.114176_bib41","doi-asserted-by":"crossref","first-page":"1522","DOI":"10.1164\/rccm.202102-0509OC","article-title":"A phase 3 open-label study of Elexacaftor\/Tezacaftor\/Ivacaftor in children 6 through 11 years of age with cystic fibrosis and at least one F508del allele","volume":"203","author":"Zemanick","year":"2021","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.jpeds.2024.114176_bib42","doi-asserted-by":"crossref","first-page":"1361","DOI":"10.1164\/rccm.202202-0392OC","article-title":"Efficacy and safety of Elexacaftor\/Tezacaftor\/Ivacaftor in children 6 through 11 years of age with cystic fibrosis heterozygous for F508del and a minimal function mutation: a phase 3b, randomized, placebo-controlled Study","volume":"206","author":"Mall","year":"2022","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.jpeds.2024.114176_bib43","doi-asserted-by":"crossref","first-page":"S227","DOI":"10.1016\/S1569-1993(23)01359-0","article-title":"Evaluation of adverse effects of elexacaftor-tezacaftor-ivacaftor in children with cystic fibrosis aged 6 to 11","volume":"22S3","author":"Pettit","year":"2023","journal-title":"J Cyst Fibros"},{"key":"10.1016\/j.jpeds.2024.114176_bib44","doi-asserted-by":"crossref","DOI":"10.1183\/13993003.02029-2022","article-title":"Long-term safety and efficacy of Elexacaftor\/Tezacaftor\/Ivacaftor in people with cystic fibrosis and at least one F508del allele: 144-week interim results from a 192-week open-label extension study","volume":"62","author":"Daines","year":"2023","journal-title":"Eur Respir J"},{"key":"10.1016\/j.jpeds.2024.114176_bib45","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1016\/j.jcf.2023.01.007","article-title":"Longitudinal effects of Elexacaftor\/Tezacaftor\/Ivacaftor on liver tests at a large single adult cystic fibrosis centre","volume":"22","author":"Tewkesbury","year":"2023","journal-title":"J Cyst Fibros"},{"key":"10.1016\/j.jpeds.2024.114176_bib46","doi-asserted-by":"crossref","first-page":"566","DOI":"10.1016\/j.jcf.2024.01.001","article-title":"Drug-induced liver injury associated with Elexacaftor\/Tezacaftor\/Ivacaftor: a pharmacovigilance analysis of the FDA adverse event reporting system (FAERS)","volume":"23","author":"Shi","year":"2024","journal-title":"J Cyst Fibros"},{"key":"10.1016\/j.jpeds.2024.114176_bib47","doi-asserted-by":"crossref","first-page":"554","DOI":"10.1016\/j.jcf.2024.04.006","article-title":"Safety and efficacy of Elexacaftor\/Tezacaftor\/Ivacaftor in people with cystic fibrosis following liver transplantation: a systematic review","volume":"23","author":"Testa","year":"2024","journal-title":"J Cyst Fibros"},{"key":"10.1016\/j.jpeds.2024.114176_bib48","doi-asserted-by":"crossref","first-page":"1179208","DOI":"10.3389\/fphar.2023.1179208","article-title":"Effects of elexacaftor\/tezacaftor\/ivacaftor therapy on mental health of patients with cystic fibrosis","volume":"14","author":"Piehler","year":"2023","journal-title":"Front Pharmacol"},{"key":"10.1016\/j.jpeds.2024.114176_bib49","doi-asserted-by":"crossref","first-page":"S22","DOI":"10.1016\/S1569-1993(23)00247-3","article-title":"WS11.01 challenging behaviours and mood changes in a large cohort of 6\u201311 year old children following Elexacaftor\/Tezacaftor\/Ivacaftor initiation","volume":"22","author":"Lee","year":"2023","journal-title":"J Cyst Fibros"},{"key":"10.1016\/j.jpeds.2024.114176_bib50","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1016\/j.jcf.2021.02.003","article-title":"Working with the CF community to understand emerging clinical and research needs for those treated with highly effective CFTR modulator therapy","volume":"20","author":"Nichols","year":"2021","journal-title":"J Cyst Fibros"},{"key":"10.1016\/j.jpeds.2024.114176_bib51","doi-asserted-by":"crossref","first-page":"917","DOI":"10.1164\/rccm.202308-1317OC","article-title":"Improvement in lung clearance index and chest computed tomography scores with Elexacaftor\/Tezacaftor\/Ivacaftor treatment in people with cystic fibrosis aged 12 years and older - the RECOVER trial","volume":"208","author":"McNally","year":"2023","journal-title":"Am J Respir Crit Care Med"}],"updated-by":[{"DOI":"10.1016\/j.jpeds.2024.114228","type":"erratum","label":"Erratum","source":"publisher","updated":{"date-parts":[[2024,11,1]],"date-time":"2024-11-01T00:00:00Z","timestamp":1730419200000}}],"container-title":["The Journal of Pediatrics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022347624002798?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022347624002798?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,10,22]],"date-time":"2024-10-22T03:48:15Z","timestamp":1729568895000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0022347624002798"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,11]]},"references-count":46,"alternative-id":["S0022347624002798"],"URL":"https:\/\/doi.org\/10.1016\/j.jpeds.2024.114176","relation":{"erratum":[{"id-type":"doi","id":"10.1016\/j.jpeds.2024.114228","asserted-by":"object"}]},"ISSN":["0022-3476"],"issn-type":[{"value":"0022-3476","type":"print"}],"subject":[],"published":{"date-parts":[[2024,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Reported Adverse Events in a Multicenter Cohort of Patients Ages 6-18\u00a0Years with Cystic Fibrosis and at Least One F508del Allele Receiving Elexacaftor\/Tezacaftor\/Ivacaftor","name":"articletitle","label":"Article Title"},{"value":"The Journal of Pediatrics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jpeds.2024.114176","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"114176"}}